Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00340665
Other study ID # 999903184
Secondary ID 03-E-N184
Status Completed
Phase
First received
Last updated
Start date May 5, 2003
Est. completion date August 22, 2012

Study information

Verified date August 22, 2012
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study, conducted at the University of Pennsylvania s Newborn Nursery, the Children s Hospital of Philadelphia, and the Exton Specialty Care Center, will examine how different infant diets may affect estrogen activity in babies. During pregnancy, babies are exposed to the female hormone estrogen from their mother. Estrogen plays a key role in the development of breasts and milk production, as well as the development of the uterus. The effects of these hormones can be seen when babies are examined. Between 6 and 12 months of age, the effects are reduced. Breast milk and some infant formulas may contain compounds that can act like female hormones in the body and may prolong the estrogen effects.

This study has two parts. Part 1 studies the physical development of babies fed different ways. Part 2 studies how hormone levels in babies differ depending on what they are being fed. Babies may participate in one or both parts. Part 1 includes babies 0 to 6 months of age; part 2 includes babies 0 to 12 months of age. In each part of the study, parents may choose to have their babies evaluated from one to four times.

Full-term infants (age 37 to 41 weeks gestational age) from birth to 12 months of age who weigh from 2501 to 4499 grams (about 5.5 to 10 pounds) at birth and who have no chromosomal abnormalities, major malformations, or endocrine problems may be eligible for this study. Male infants must have palpable testes. Infants being fed a diet of breast milk, soy milk, or cow s milk will be included. Study procedures include the following:

Part 1

- Feeding history: the parent provides information about the baby s dietary intake since birth.

- Length, weight, and head circumference: the baby s measurements are taken.

- Physical examination: the baby s physical maturity is assessed by examination of the skin, breasts, and external sex organs.

- Breast secretions: the baby s breast buds are gently pressed during the physical examination to look for a milky-white substance that some babies produce during the first year of life. If the substance appears, a specimen will be collected.

- Vaginal cells: for baby girls, the opening of the vaginal area is gently swabbed with a sterile Q-tip to assess the maturity of the vaginal lining.

Part 2

- Feeding history and length, weight and head circumference measurements as described above.

- Urine: a urine sample is collected in a cotton diaper or a urine collection bag.

- aliva: a saliva sample is collected by gently swabbing the inside of the baby s mouth 1 hour after a morning feeding to remove any left over milk.

- Hair: a lock of hair, 1/2-inch wide and 1 to 2 inches long is taken from 12-month old babies.

- Blood: some infants have a small blood sample collected by a heel-stick.

This study will serve as a basis for a later study about how infant formulas affect infant growth.


Description:

Term newborns have anatomic and sonographic evidence of in utero estrogen exposure. Over the first six months to a year of life, as the influence of maternal hormone wanes, these findings recede. Soy infant formula contains large amounts of isoflavones (diadzein and genistein) that can occupy estrogen receptors and act as estrogens in the laboratory. A food substance with estrogen activity might prolong the effect of maternal hormones, or interfere with hormonal homeostasis the child. Two cross-sectional pilot study (SEAD 2 and SEAD 3) will be undertaken in order to establish the methods for a future, multi-center study designed to assess the potential effects of soy formula on estrogen activity in infants. Another cross-sectional pilot study (SEAD 1) will be undertaken to evaluate anatomical evidence detected by ultrasound and will be conducted at The Children's Hospital in Boston. Details of the SEAD 1 study will not be presented in this protocol. In the first pilot study (SEAD 2), 84 examinations of full-term infants, ages 0-6 months and on one of three feeding regimens (soy formula, breast milk or cow's milk formula) will be conducted. This study will establish a protocol for examining and sampling methods to be used for a later trial investigating whether exposure to soy estrogen compared to breast milk and non-soy formulas prolongs anatomical evidence of estrogen exposure and response. In addition to the physical examination, vaginal cells will be collected for cytology analysis. Breast nipple secretions, if present, will also be collected and analyzed for protein and sugar levels. In the second pilot study (SEAD 3), 372 evaluations on full-term infants will be conducted in parallel with the first study. SEAD 3 will assess the hormonal and biochemical status of full-term infants age 0-12 months. This study will establish a protocol for sampling methods to be used for collecting urine, saliva, serum, and hair samples. Endogenous hormone levels such as testosterone, estradiol, and isoflavone levels (genestein and diadzein) will be measured in serum and the results will be compared against the non-serum tests (urine, saliva and hair). The purpose of these two pilot studies is twofold. The first is to develop and finalize recruitment and collections procedures in preparation for a larger, comprehensive trial of biological response in children to soy formula with and without the estrogenic isoflavones. The second is to study the natural history of estrogen activity in infants on a variety of feeding regimens.


Recruitment information / eligibility

Status Completed
Enrollment 239
Est. completion date August 22, 2012
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group N/A to 1 Year
Eligibility - INCLUSION CRITERIA:

SEAD 2 and 3

1. Full term infants defined as age 37-41 weeks gestational age at birth. Ultrasound evidence or reliable reporting of last menstrual period (LMP) by infant's mother.

2. Can be categorized into one of the feeding definitions.

3. Birth weight between 2501-4499 grams.

4. Age 0-6 months for SEAD 2, age 0-12 months for SEAD 3

5. For SEAD 3, for 12-months age interval, subjects must not have had first haircut.

EXCLUSION CRITERIA:

SEAD 2 and 3

1. Chromosomal aberrations

2. Major malformation

3. SEAD 2: Non-palpable testis (males only)

4. Presence of an endocrinopathy (i.e., ambiguous genitalia, congenital hypothyroidism)

This is a natural history study and children must be healthy in order to participate in this study. Therefore, children will be excluded from the study if they are known to have chromosomal aberrations, or any major malformations or an endocrinopathy. Testicular development is an important endpoint in this study and therefore males will be excluded from SEAD 2 if the testes are not palpable.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Childrens Hospital, Philadelphia Philadelphia Pennsylvania
United States University of Pennsylvania Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Environmental Health Sciences (NIEHS)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Cruz ML, Wong WW, Mimouni F, Hachey DL, Setchell KD, Klein PD, Tsang RC. Effects of infant nutrition on cholesterol synthesis rates. Pediatr Res. 1994 Feb;35(2):135-40. — View Citation

Setchell KD, Zimmer-Nechemias L, Cai J, Heubi JE. Isoflavone content of infant formulas and the metabolic fate of these phytoestrogens in early life. Am J Clin Nutr. 1998 Dec;68(6 Suppl):1453S-1461S. doi: 10.1093/ajcn/68.6.1453S. Review. — View Citation

Strom BL, Schinnar R, Ziegler EE, Barnhart KT, Sammel MD, Macones GA, Stallings VA, Drulis JM, Nelson SE, Hanson SA. Exposure to soy-based formula in infancy and endocrinological and reproductive outcomes in young adulthood. JAMA. 2001 Aug 15;286(7):807-14. — View Citation

See also
  Status Clinical Trial Phase
Recruiting NCT05578716 - Growth, Allergy and Neurodevelopment in Infants on Hydrolysed Formula N/A
Not yet recruiting NCT06318117 - Reason for Prescribing Rice Infant Formula
Completed NCT05224947 - Gastric Layering and Monitoring II N/A
Completed NCT01625273 - Supplementation of Infant Formula With Synbiotics N/A
Completed NCT05097924 - Gastrointestinal Tolerability of a Partially Hydrolyzed Ready-to-feed Infant Formula in Healthy Newborns
Recruiting NCT05992493 - The Role of Human Milk Oligosaccharides and Microbiomes on Infantile Colic and Atopic Dermatitis in Term Infants
Completed NCT03456934 - Lower Protein Intake and Long-term Risk of Obesity and Cardiovascular Disease N/A
Recruiting NCT05868408 - Effect of Partially Hydrolyzed, Whey-based Infant Formulas on Growth and Tolerability in Healthy Term Infants N/A
Completed NCT05295030 - Effects of Breast Milk Simulated Infant Formula N/A